Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 5/20 | 0.37 |
| ▸ | MEN1 | O00255 | 4/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 2/20 | 0.34 |
| ▸ | ALOX5AP | P20292 | 2/20 | 0.34 |
| ▸ | MAPT | P10636 | 2/20 | 0.34 |
| ▸ | PDE2A | O00408 | 4/20 | 0.33 |
| ▸ | SCD | O00767 | 2/20 | 0.33 |
| ▸ | RBP1 | P09455 | 3/20 | 0.32 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23578231 | 0.88 | MEN1 (0.37) | KMT2AMEN1HTTLMNAALOX5AP | |
| SCHEMBL23588185 | 0.86 | KMT2A (0.39) | KMT2AMEN1HTTLMNAALOX5AP | |
| SCHEMBL25805322 | 0.86 | KMT2A (0.40) | KMT2AMEN1HTTLMNAALOX5AP | |
| SCHEMBL25801899 | 0.86 | KMT2A (0.35) | KMT2AMEN1HTTLMNAALOX5AP | |
| SCHEMBL23588314 | 0.85 | PDE2A (0.37) | KMT2AMEN1HTTLMNAALOX5AP | |
| SCHEMBL23578057 | 0.85 | KMT2A (0.36) | KMT2AMEN1HTTLMNAALOX5AP | |
| SCHEMBL23578431 | 0.85 | S1PR1 (0.39) | KMT2AMEN1HTTLMNAALOX5AP | |
| SCHEMBL23588183 | 0.84 | KMT2A (0.39) | KMT2AMEN1HTTLMNAALOX5AP | |
| SCHEMBL23578427 | 0.84 | KMT2A (0.39) | KMT2AMEN1HTTLMNAALOX5AP | |
| SCHEMBL23578175 | 0.84 | KMT2A (0.39) | KMT2AMEN1HTTLMNAALOX5AP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230219907-A1 | CARBOXY DERIVATIVES WITH ANTIINFLAMATORY PROPERTIES | SITRYX THERAPEUTICS LIMITED (GB) | 2023-07-13 | — | — | US | disclosed |
| US-20230219907-A1 | CARBOXY DERIVATIVES WITH ANTIINFLAMATORY PROPERTIES | SITRYX THERAPEUTICS LIMITED (GB) | 2023-07-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230219907-A1 | CARBOXY DERIVATIVES WITH ANTIINFLAMATORY PROPERTIES | CPA2, RO60, C5AR1 | KMT2A 3125/4885MEN1 4504/4885HTT 4546/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.